[Federal Register Volume 85, Number 43 (Wednesday, March 4, 2020)]
[Page 12811]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-04408]



Advisory Committee on the Medical Uses of Isotopes Charter 

AGENCY: Nuclear Regulatory Commission.

ACTION: Notice of renewal of the charter of the Advisory Committee on 
the Medical Uses of Isotopes.


SUMMARY: The U.S. Nuclear Regulatory Commission (NRC) has determined 
that renewal of the charter for the Advisory Committee on the Medical 
Uses of Isotopes (ACMUI) until February 28, 2022, is in the public 
interest in connection with duties imposed on the Commission by law. 
This action is being taken in accordance with the Federal Advisory 
Committee Act, after consultation with the Committee Management 
Secretariat, General Services Administration.
    The purpose of the ACMUI is to provide advice to the NRC on policy 
and technical issues that arise in regulating the medical use of 
byproduct material for diagnosis and therapy. Responsibilities include 
providing guidance and comments on current and proposed NRC regulations 
and regulatory guidance concerning medical use; evaluating certain non-
routine uses of byproduct material for medical use; and evaluating 
training and experience of proposed authorized users. The members are 
involved in preliminary discussions of major issues in determining the 
need for changes in NRC policy and regulation to ensure the continued 
safe use of byproduct material. Each member provides technical 
assistance in his/her specific area(s) of expertise, particularly with 
respect to emerging technologies. Members also provide guidance as to 
NRC's role in relation to the responsibilities of other Federal 
agencies as well as of various professional organizations and boards.
    Members of this Committee have demonstrated professional 
qualifications and expertise in both scientific and non-scientific 
disciplines including nuclear medicine; nuclear cardiology; radiation 
therapy; medical physics; nuclear pharmacy; State medical regulation; 
patient's rights and care; health care administration; and Food and 
Drug Administration regulation.

Contact Information: Kellee Jamerson, Office of Nuclear Material Safety 
and Safeguards, U.S. Nuclear Regulatory Commission, Washington, DC 
20555; Telephone: (301) 415-7408 or at [email protected].

    Dated: February 28, 2020.
Russell E. Chazell,
Federal Advisory Committee Management Officer.
[FR Doc. 2020-04408 Filed 3-3-20; 8:45 am]